645 related articles for article (PubMed ID: 26988947)
1. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
[TBL] [Abstract][Full Text] [Related]
3. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
[TBL] [Abstract][Full Text] [Related]
4. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry.
Kayıkcioglu M; Başaran Ö; Doğan V; Mert KU; Mert GÖ; Özdemir İH; Rencüzoğulları İ; Karadeniz FÖ; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Cinier G; Akay KH; Pekel N; Utku Şenol ; Demir V; İnci S; Derviş E; Özlek B; Özlek E; Çelik O; Çil C; Biteker M
J Clin Lipidol; 2023; 17(6):732-742. PubMed ID: 38072583
[TBL] [Abstract][Full Text] [Related]
5. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.
Peretti N; Vimont A; Mas E; Lemale J; Reynaud R; Tounian P; Poinsot P; Restier L; Paillard F; Pradignac A; Pucheu Y; Rabès JP; Bruckert E; Gallo A; Béliard S
Arch Pediatr; 2024 Apr; 31(3):188-194. PubMed ID: 38538465
[TBL] [Abstract][Full Text] [Related]
6. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
[TBL] [Abstract][Full Text] [Related]
7. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
Alonso R; Arroyo-Olivares R; Muñiz-Grijalvo O; Díaz-Díaz JL; Muñoz-Torrero JS; Romero MJ; de Andrés R; Zambón D; Mañas MD; Fuentes-Jiménez F; Aguado R; Alvarez-Baños P; Arrieta F; Gonzalez-Bustos P; Cepeda J; Martin-Ordiales M; Mosquera D; Michan A; de Isla LP; Argueso R; Mata P
Eur J Prev Cardiol; 2023 Mar; 30(4):320-328. PubMed ID: 36416136
[TBL] [Abstract][Full Text] [Related]
8. Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics.
Chua YA; Nazli SA; Rosman A; Kasim SS; Ibrahim KS; Md Radzi AB; Mohd Kasim NA; Nawawi H
J Atheroscler Thromb; 2023 Oct; 30(10):1317-1326. PubMed ID: 36567112
[TBL] [Abstract][Full Text] [Related]
9. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
Schreuder MM; Hamkour S; Siegers KE; Holven KB; Johansen AK; van de Ree MA; Imholz B; Boersma E; Louters L; Bogsrud MP; Retterstøl K; Visseren FLJ; Roeters van Lennep JE; Koopal C
Atherosclerosis; 2023 Nov; 384():117117. PubMed ID: 37080805
[TBL] [Abstract][Full Text] [Related]
10. Lipid management across Europe in the real-world setting: a rapid evidence review.
Barrios V; Soronen J; Carter AM; Anastassopoulou A
Curr Med Res Opin; 2021 Dec; 37(12):2049-2059. PubMed ID: 34517739
[TBL] [Abstract][Full Text] [Related]
11. Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia.
Climent E; Marco-Benedí V; Benaiges D; Pintó X; Suárez-Tembra M; Plana N; Lafuente H; Ortega-Martínez de Victoria E; Brea-Hernando Á; Vila À; Civeira F; Pedro-Botet J
Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1594-1603. PubMed ID: 33744038
[TBL] [Abstract][Full Text] [Related]
12. Familial Hypercholesterolemia: Global Burden and Approaches.
Tokgozoglu L; Kayikcioglu M
Curr Cardiol Rep; 2021 Sep; 23(10):151. PubMed ID: 34480646
[TBL] [Abstract][Full Text] [Related]
13. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C.
Katzmann JL; Sorio-Vilela F; Dornstauder E; Fraas U; Smieszek T; Zappacosta S; Laufs U
Clin Res Cardiol; 2022 Mar; 111(3):243-252. PubMed ID: 32949286
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.
Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; de Andrés R; Arroyo-Olivares R; Fuentes-Jimenez F; Muñoz-Torrero JS; Cepeda J; Aguado R; Alvarez-Baños P; Casañas M; Dieguez M; Mañas MD; Rubio P; Argueso R; Arrieta F; Gonzalez-Bustos P; Perez-Isla L; Mata P;
J Clin Lipidol; 2021; 15(4):584-592. PubMed ID: 34052174
[TBL] [Abstract][Full Text] [Related]
15. Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry.
de Ferranti SD; Shrader P; Linton MF; Knowles JW; Hudgins LC; Benuck I; Kindt I; O'Brien EC; Peterson AL; Ahmad ZS; Clauss S; Duell PB; Shapiro MD; Wilemon K; Gidding SS; Neal W
J Pediatr; 2021 Feb; 229():70-77. PubMed ID: 32976895
[TBL] [Abstract][Full Text] [Related]
16. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
[TBL] [Abstract][Full Text] [Related]
17. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
18. Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.
Rizos CV; Florentin M; Skoumas I; Tziomalos K; Rallidis L; Kotsis V; Athyros V; Skalidis E; Kolovou G; Garoufi A; Bilianou E; Koutagiar I; Agapakis D; Kiouri E; Antza C; Katsiki N; Zacharis E; Attilakos A; Sfikas G; Anagnostis P; Panagiotakos DB; Liberopoulos EN
Lipids Health Dis; 2020 May; 19(1):114. PubMed ID: 32466791
[TBL] [Abstract][Full Text] [Related]
19. Treatment Inertia in Patients With Familial Hypercholesterolemia.
Langer A; Mancini GBJ; Tan M; Goodman SG; Ahooja V; Grégoire J; Lin PJ; Stone JA; Leiter LA
J Am Heart Assoc; 2021 Jul; 10(14):e020126. PubMed ID: 34238023
[TBL] [Abstract][Full Text] [Related]
20. Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents.
Cohen H; Stefanutti C;
Curr Atheroscler Rep; 2021 May; 23(6):30. PubMed ID: 33963467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
